Agios Pharmaceuticals (AGIO) Earning Somewhat Favorable Media Coverage, Analysis Finds
Headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.5514442919916 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern’s rankings:
- Agios Pharmaceuticals Inc (AGIO) RMI Running Higher in Consecutive Sessions – Evergreen Caller (evergreencaller.com)
- Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y – Nasdaq (nasdaq.com)
- Bb Biotech Ag Increases Its Holdings in Agios Pharmaceuticals, Inc. (AGIO) Stock – Modern Readers (modernreaders.com)
- Leerink Swann Comments on Agios Pharmaceuticals, Inc.’s FY2017 Earnings (NASDAQ:AGIO) (americanbankingnews.com)
- Agios Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($1.78) Per Share, SunTrust Banks Forecasts (NASDAQ:AGIO) (americanbankingnews.com)
Agios Pharmaceuticals (NASDAQ:AGIO) traded up 1.03% on Friday, hitting $58.86. 501,674 shares of the stock traded hands. The company’s market capitalization is $2.85 billion. The firm has a 50-day moving average price of $56.90 and a 200-day moving average price of $51.87. Agios Pharmaceuticals has a 12 month low of $35.84 and a 12 month high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by $0.21. The company had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business’s revenue for the quarter was up 62.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.47) earnings per share. Analysts forecast that Agios Pharmaceuticals will post ($6.90) earnings per share for the current year.
Several research analysts have issued reports on the stock. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 target price (up from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday. Needham & Company LLC lifted their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 target price (up from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday. Cann reaffirmed a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Finally, Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $50.00 to $80.00 in a report on Wednesday, August 2nd. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $74.75.
In related news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total value of $95,895.60. Following the completion of the transaction, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David P. Schenkein sold 3,000 shares of the stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $50.02, for a total transaction of $150,060.00. Following the completion of the transaction, the chief executive officer now directly owns 1,100 shares of the company’s stock, valued at $55,022. The disclosure for this sale can be found here. Insiders sold a total of 79,120 shares of company stock valued at $4,557,207 over the last ninety days. 10.55% of the stock is currently owned by insiders.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.